"The magnitude of this achievement is one of a kind and we predict will be disruptive in the future to the implantable device marketplace."

— Michael Dale, president/CEO of ATS Medical, discussing the company's ongoing development of a technology designed to control the initial interaction between blood and an artificial device, "Forcefield animal study proves long-term effect, ATS says," pp. 1, 9.